Pediatrix Medical Group (NYSE:MD) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a research note released on Wednesday morning.

MD has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft boosted their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. UBS Group boosted their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Jefferies Financial Group increased their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Mizuho lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Finally, Truist Financial upped their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Pediatrix Medical Group has a consensus rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Trading Down 4.1 %

NYSE MD opened at $14.15 on Wednesday. Pediatrix Medical Group has a 12 month low of $6.62 and a 12 month high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. The stock has a 50 day moving average of $12.53 and a 200-day moving average of $9.84. The company has a market cap of $1.22 billion, a PE ratio of -4.62, a PEG ratio of 2.18 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the company posted $0.29 earnings per share. On average, equities research analysts anticipate that Pediatrix Medical Group will post 1.25 EPS for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In related news, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. The trade was a 18.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,808 shares of company stock worth $751,277 in the last ninety days. 2.00% of the stock is owned by company insiders.

Institutional Trading of Pediatrix Medical Group

A number of institutional investors have recently modified their holdings of MD. nVerses Capital LLC bought a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $31,000. Innealta Capital LLC acquired a new position in Pediatrix Medical Group during the second quarter valued at approximately $33,000. Quest Partners LLC lifted its stake in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares in the last quarter. Finally, Quarry LP increased its stake in shares of Pediatrix Medical Group by 54.1% in the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,662 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.